Search research articles
Contact Us
Filters
Showing results (21-30 of 84) with videos related to
Page
of 9
Sort By:
Expert Opinion on Therapeutic Patents
|
August 25, 2012
Aryl amide derivatives of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine derivatives useful as ASK1 inhibitors, an evaluation of WO2012080735
Peter Norman
Expert Opinion on Therapeutic Patents
|
August 25, 2012
Evaluation of WO-2012085582 and WO-2012085583 two identified MABAs: backups to AZD-2115?
Peter Norman
Drug News & Perspectives
|
April 5, 2003
Chemotherapeutic Strategies in the Challenge of Cancer Treatment
Peter Norman
Expert Opinion on Therapeutic Patents
|
June 10, 2009
BMS-582949: crystalline form of a p38alpha inhibitor? WO2008079857
Peter Norman
Expert Opinion on Therapeutic Patents
|
July 10, 2009
AZD-4818, a chemokine CCR1 antagonist: WO2008103126 and WO2009011653
Peter Norman
Expert Opinion on Therapeutic Patents
|
February 24, 2012
Evaluation of WO2011134971, chiral 1,6-napthyridine Syk kinase inhibitors
Peter Norman
Expert Opinion on Therapeutic Patents
|
January 13, 2011
Crystalline form of a neutrophil elastase inhibitor, 6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-{[5-(methylsulfonyl)pyridin-2-yl]methyl}-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide p-toluene sulfonate - is it AZD-9668?: WO-2010094964
Peter Norman
Expert Opinion on Therapeutic Patents
|
April 22, 2014
The use of salt-inducible kinase inhibitors to treat autoimmune and inflammatory diseases: evaluation of WO2013136070
Peter Norman
Expert Opinion on Therapeutic Patents
|
July 7, 2012
Evaluation of WO2012032067 and WO2012055846: two selective PI3Kδ inhibitors, which is GSK-2269557?
Peter Norman
Expert Opinion on Therapeutic Patents
|
July 10, 2012
Evaluation of WO2012037204 and WO2012037226: Exelixis' selective PI3Kδ inhibitors; the basis of a US$251 million deal
Peter Norman
Page
of 9
Search research articles
Search
Showing results (21-30 of 84) with videos related to
Sort By:
Page
of 9
Expert Opinion on Therapeutic Patents
|
August 25, 2012
Aryl amide derivatives of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine derivatives useful as ASK1 inhibitors, an evaluation of WO2012080735
Peter Norman
Expert Opinion on Therapeutic Patents
|
August 25, 2012
Evaluation of WO-2012085582 and WO-2012085583 two identified MABAs: backups to AZD-2115?
Peter Norman
Drug News & Perspectives
|
April 5, 2003
Chemotherapeutic Strategies in the Challenge of Cancer Treatment
Peter Norman
Expert Opinion on Therapeutic Patents
|
June 10, 2009
BMS-582949: crystalline form of a p38alpha inhibitor? WO2008079857
Peter Norman
Expert Opinion on Therapeutic Patents
|
July 10, 2009
AZD-4818, a chemokine CCR1 antagonist: WO2008103126 and WO2009011653
Peter Norman
Expert Opinion on Therapeutic Patents
|
February 24, 2012
Evaluation of WO2011134971, chiral 1,6-napthyridine Syk kinase inhibitors
Peter Norman
Expert Opinion on Therapeutic Patents
|
January 13, 2011
Crystalline form of a neutrophil elastase inhibitor, 6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-{[5-(methylsulfonyl)pyridin-2-yl]methyl}-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide p-toluene sulfonate - is it AZD-9668?: WO-2010094964
Peter Norman
Expert Opinion on Therapeutic Patents
|
April 22, 2014
The use of salt-inducible kinase inhibitors to treat autoimmune and inflammatory diseases: evaluation of WO2013136070
Peter Norman
Expert Opinion on Therapeutic Patents
|
July 7, 2012
Evaluation of WO2012032067 and WO2012055846: two selective PI3Kδ inhibitors, which is GSK-2269557?
Peter Norman
Expert Opinion on Therapeutic Patents
|
July 10, 2012
Evaluation of WO2012037204 and WO2012037226: Exelixis' selective PI3Kδ inhibitors; the basis of a US$251 million deal
Peter Norman
Page
of 9